Rosetta Genomics Receives Key U.S. Patent Allowance

Rosetta Genomics, Ltd. ROSG today announced receipt of a patent allowance from the U.S. Patent and Trademark Office for Patent Application 12/800,556 titled, "MICRORNAS AND USES THEREOF." The allowed claims cover the composition of matter for miR-378, a core element of Rosetta Genomics' microRNA technology used in its miRview® mets and miRview® mets2 diagnostic tests for the accurate identification of the primary tumor type in Cancer of Unknown Primary patients as well as cancer patients with difficult to diagnose metastases. Once issued, this patent will provide protection through May 2024. The allowed claims provide for miR-378 as a specific microRNA sequence, as well as sequence variants, as opposed to general mechanisms or concepts. The allowed claims are directed to novel technologies that can be used for detecting and profiling microRNAs, and have application in the use of microRNA-378 as diagnostic biomarkers and therapeutics targets.